"Landscape of Phase 2 Trials in Alzheimer's Disease": Perspective on Adaptive Trials

Better means of conducting more efficient clinical trials for the development of Alzheimer's disease (AD) therapeutics are required. Adaptive clinical trial designs have many advantages based on the ability to make prespecified changes in the trial conduct depending on the ongoing experience in the trial. In their report in the Journal of Alzheimer's Disease, Lee and colleagues show that in the past 25 years only 2.5% of AD clinical trials have used adaptive designs. The report calls attention to the opportunity to use adaptive designs more often in Phase 2 clinical trials to improve trial efficiency and accelerate treatment development.